A new study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify ...
Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...
Introduction: Multiple sclerosis (MS) and rheumatoid arthritis (RA) are common, chronic immune-mediated diseases that share pathogenetic pathways, but their epidemiological relationship is uncertain.
The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...
—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. A growing body ...
Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...
The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
Resistance training is effective for improving gait speed in individuals with multiple sclerosis. The intensity and duration of resistance training are important factors in determining the magnitude ...
Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...
Find out how combined chemical exposures and genetics may raise multiple sclerosis risk in new population research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback